Champlain Investment Partners LLC Trims Position in Glaukos Corporation $GKOS

Champlain Investment Partners LLC trimmed its position in shares of Glaukos Corporation (NYSE:GKOS) by 1.3% during the 3rd quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 358,419 shares of the medical instruments supplier’s stock after selling 4,607 shares during the period. Champlain Investment Partners LLC’s holdings in Glaukos were worth $29,229,000 at the end of the most recent reporting period.

Several other hedge funds also recently bought and sold shares of GKOS. Riverbridge Partners LLC boosted its position in shares of Glaukos by 41.0% during the third quarter. Riverbridge Partners LLC now owns 569,644 shares of the medical instruments supplier’s stock worth $46,454,000 after acquiring an additional 165,673 shares during the last quarter. JPMorgan Chase & Co. increased its holdings in Glaukos by 4.3% in the 3rd quarter. JPMorgan Chase & Co. now owns 670,083 shares of the medical instruments supplier’s stock valued at $54,645,000 after acquiring an additional 27,646 shares during the last quarter. Holocene Advisors LP lifted its stake in Glaukos by 40.1% in the 2nd quarter. Holocene Advisors LP now owns 1,045,886 shares of the medical instruments supplier’s stock worth $108,030,000 after purchasing an additional 299,118 shares in the last quarter. Baird Financial Group Inc. boosted its holdings in shares of Glaukos by 17.7% during the 2nd quarter. Baird Financial Group Inc. now owns 63,379 shares of the medical instruments supplier’s stock valued at $6,546,000 after purchasing an additional 9,545 shares during the last quarter. Finally, Public Sector Pension Investment Board grew its position in shares of Glaukos by 14.8% during the third quarter. Public Sector Pension Investment Board now owns 223,708 shares of the medical instruments supplier’s stock valued at $18,243,000 after purchasing an additional 28,866 shares in the last quarter. Institutional investors own 99.04% of the company’s stock.

Insider Transactions at Glaukos

In related news, Director Marc Stapley sold 15,000 shares of Glaukos stock in a transaction dated Thursday, January 22nd. The shares were sold at an average price of $127.71, for a total transaction of $1,915,650.00. Following the completion of the transaction, the director directly owned 37,449 shares of the company’s stock, valued at approximately $4,782,611.79. The trade was a 28.60% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. Also, COO Joseph E. Gilliam sold 10,498 shares of the company’s stock in a transaction dated Thursday, January 22nd. The shares were sold at an average price of $127.68, for a total transaction of $1,340,384.64. Following the transaction, the chief operating officer owned 92,366 shares in the company, valued at $11,793,290.88. The trade was a 10.21% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. In the last ninety days, insiders have sold 325,000 shares of company stock worth $37,739,259. 6.40% of the stock is currently owned by insiders.

Glaukos Price Performance

NYSE:GKOS opened at $117.63 on Wednesday. The firm has a market capitalization of $6.83 billion, a price-to-earnings ratio of -36.08 and a beta of 0.70. The company has a debt-to-equity ratio of 0.10, a current ratio of 4.69 and a quick ratio of 4.06. The business has a 50 day simple moving average of $116.12 and a 200-day simple moving average of $100.55. Glaukos Corporation has a 1 year low of $73.16 and a 1 year high of $130.23.

Glaukos (NYSE:GKOS) last released its earnings results on Tuesday, February 17th. The medical instruments supplier reported ($0.28) earnings per share for the quarter, missing the consensus estimate of ($0.22) by ($0.06). The company had revenue of $143.12 million for the quarter, compared to the consensus estimate of $132.16 million. Glaukos had a negative net margin of 36.99% and a negative return on equity of 7.00%. The business’s revenue for the quarter was up 35.6% compared to the same quarter last year. During the same period in the prior year, the firm posted ($0.40) EPS. Equities analysts forecast that Glaukos Corporation will post -1.08 EPS for the current year.

Analysts Set New Price Targets

A number of equities research analysts recently commented on GKOS shares. Stifel Nicolaus boosted their target price on Glaukos from $115.00 to $160.00 and gave the stock a “buy” rating in a research report on Thursday, January 22nd. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Glaukos in a research note on Thursday, January 22nd. BTIG Research reaffirmed a “buy” rating and set a $131.00 price objective on shares of Glaukos in a report on Wednesday, February 18th. Truist Financial increased their target price on Glaukos from $120.00 to $145.00 and gave the company a “buy” rating in a research report on Thursday, December 18th. Finally, Wall Street Zen lowered shares of Glaukos from a “buy” rating to a “hold” rating in a report on Saturday, February 21st. One analyst has rated the stock with a Strong Buy rating, twelve have given a Buy rating, one has assigned a Hold rating and two have assigned a Sell rating to the stock. According to data from MarketBeat.com, Glaukos currently has a consensus rating of “Moderate Buy” and a consensus price target of $133.69.

Glaukos Profile

Glaukos Corporation is a medical technology company specializing in the development, manufacturing and commercialization of innovative therapies for patients with glaucoma and other chronic eye diseases. The company’s core offerings focus on micro-invasive glaucoma surgery (MIGS), designed to reduce intraocular pressure and manage glaucoma more safely and effectively than traditional surgical approaches. Glaukos’s flagship products include the iStent, iStent inject and iStent infinite trabecular micro-bypass stents, which are implanted during cataract surgery to improve aqueous outflow and help control eye pressure.

Beyond its MIGS portfolio, Glaukos has expanded into sustained drug-delivery solutions.